As with most other malignancies, patients with early-stage disease at diagnosis and better performance status have a good prognosis; whereas, advanced disease, poor performance status, and weight loss are indicators of poor outcomes. Also, metastatic NSCLC patients eligible for treatment with targeted therapies have a better prognosis compared with those without targetable genomic variations.

It is very important to promptly identify the symptoms and diagnose Pancoast syndrome as they are usually stage IIB or higher by the time they are diagnosed. Early detection, staging,Â and treatment are therefore critical for long-term survival.